Martin L. Sos
German Cancer Research Center · 258 works · 16,062 citations · h-index 43
Top works
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
- Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
- Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions
- Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
- PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
- Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
- Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation
- Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants
- MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
- Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
- Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors
- ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
- A crucial requirement for Hedgehog signaling in small cell lung cancer
- K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways
- Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer
- Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
- Characteristics of Lung Cancers Harboring NRAS Mutations